1	Clinical evaluation of a fully automated, lab developed multiplex RT-PCR
2	assay integrating dual-target SARS-CoV-2 and Influenza-A/B detection on a
3	high-throughput platform
4	Dominik Nörz ¹ , Armin Hoffmann ¹ , Martin Aepfelbacher ¹ , Susanne Pfefferle ¹ * and Marc
5	Lütgehetmann ¹ *
6	1 University Medical Center Hamburg-Eppendorf (UKE), Institute of Medical Microbiology, Virology
7	and Hygiene, Hamburg, Germany
8	
9	* Equal contribution
10	Highlights:
11	• Simultaneous detection of highly pathogenic respiratory viruses Influenza-A/B and
12	SARS-CoV-2
13	 Including a dual-target assay for SARS-CoV-2 detection
14	 Full automation on the cobas6800 high-throughput platform
15	
16	
17	
18	
19	
20	
21	
22	
23	Address correspondence to:
24	
25	Marc Lütgehetmann
26	Institute of Medical Microbiology, Virology and Hygiene
27	Martinistraße 52
28	D-20246 Hamburg
29	mluetgen@uke.de
30	

31 **1 Abstract**

32 Background: Laboratories worldwide face high demands for molecular testing during the SARS-CoV-2 pandemic that might be further aggravated with the upcoming influenza season 33 34 in the northern hemisphere. Considering that symptoms of influenza are largely undistinguishable from COVID-19, both SARS-CoV-2 and the Influenza viruses require 35 concurrent testing by RT-PCR in patients presenting with symptoms of respiratory tract 36 37 infection. In this study, we adapted and evaluated a laboratory developed multiplex RT-PCR 38 assay for simultaneous detection of SARS-CoV-2 (dual-target), Influenza-A and Influenza-B (SC2/InflA/InflB-UCT) on a fully automated high-throughput system (cobas6800). Methods: 39 Analytical performance was assessed by serial dilution of guantified reference material and 40 41 cell culture stocks in transport medium, including pre-treatment for chemical inactivation. 42 For clinical evaluation, residual portions of 164 predetermined patient samples containing 43 SARS-CoV-2 (n=52), Influenza-A (n=43) or Influenza-B (n=19), as well as a set of negative 44 samples was subjected to the novel multiplex assay. Results: The assay demonstrated 45 analytical performance comparable to currently available commercial tests, with limits of detection of 94.9 cp/ml for SARS-CoV-2, 14.6 cp/ml for Influenza-A and 422.3 cp/ml for 46 Influenza-B. Clinical evaluation showed excellent agreement with the comparator assays 47 (sensitivity 98.1%, 97.7% and 100% for Sars-CoV-2, Influenza-A and -B respectively). 48 **Conclusion:** The SC2/InflA/InflB-UCT allows for efficient high-throughput testing for all three 49 50 pathogens and thus provides streamlined diagnostics while conserving resources during the Influenza-season. 51

52 2 Introduction:

The upcoming Influenza-season of 2020/21 will further aggravate the strain on diagnostic 53 laboratories, already facing unprecedented demand for molecular diagnostics due to the 54 ongoing SARS-CoV-2 pandemic. Just like COVID-19, Influenza is a major concern for infection 55 56 control within healthcare facilities and symptoms are largely indistinguishable, particularly in the early phase of disease (1, 2). Consequently, SARS-CoV-2 and the Influenza viruses need 57 to be concurrently tested for by RT-PCR before contact precaution measures can be lifted for 58 59 symptomatic patients. In light of the continuing worldwide shortage of supplies for nucleic 60 acid extraction and PCR diagnostics, it appears desirable to be able to screen for all three 61 viruses (SARS-CoV-2, Influenza-A and Influenza-B) within the same reaction. 62 The cobas6800 system is a fully automated sample-to-result high-throughput platform, 63 requiring minimal hands-on-time and able to perform up to 384-tests in an 8-hour shift. The 64 instrument was previously evaluated for the detection of Influenza viruses in respiratory 65 swabs (3) and is currently seeing increasing use for automated SARS-CoV-2 diagnostics (4, 5).

The aim of this study was to establish and evaluate a multiplex assay for the detection of SARS-CoV-2, Influenza-A and Influenza-B on the open mode of the cobas6800 system (cobas omni utility channel).

69 **3 Materials and Methods**

70 3.1 SC2/InfIA/InfIB-UCT setup and preparation

A set of published RT-PCR assays for SARS-CoV-2, Influenza-A- and Influenza-B virus was selected and adapted for use on the cobas6800 system, see *table 1* (6-10). Primers were

- 73 modified with 2'O-methylated RNA-bases at their penultimate positions to reduce formation
- of primer dimers. Double-quenched probes were used to lower background-fluorescence. All
- 75 primers and probes were tested for contaminations prior to use, in particular concerning
- 76 material reactive for SARS-CoV-2 in custom made commercial primers.

Target	Primer/Probe	Sequence (5' - 3')	Conc. [nM]	Indusivity	Ref.
SARS-CoV- 2 E-Gene	Fwd: Rev: Probe:	ACAGGTACGTTAATAGTTAATAGC (OMe-G) T ATATTGCAGCAGTACG CACA (OMe-C)A Fam-ACACTAGCC (ZEN-NFQ)ATCCTTACTGCGCTTCG - Iowa Black	400 400 50	Sarbecovirus (SARS-CoV, SARS-CoV-2)	[6]
SARS-CoV- 2 RdRp/Hel	Fwd: Rev: Probe:	CGCATACAGTCTTACAGG(OMe-C)T TGTGATGTTGATATGATATGG(OMe-U)C Fam- TTAAGATGT(ZEN-NFQ)GGTGCTTGCATACGTAGAC - Io wa Black	300 300 50	SARS- CoV- 2	[7]
Influenza A M	Fwd: Rev: Probe:	CTTCTAACCGAGGTCGAAACG (OMe-U) A GGTGACAGGATTGGTCTTGTCTT (OMe-U) A YakYel- TCAGGCCCC(ZEN-NFQ)CTCAAAGCCGAG -lowaBlack	300 300 50	Pan-Influenza-A (incl. avian H5 and H7)	[8,9]
Influenza B NS2	Fwd: Rev: Probe:	TCCTCAAYTCACTCTTCGAG(OMe-C)G CGGTGCTCTTGACCAAATT(OMe-G)G Atto620- CCAATTCGA(BMN-Q620)GCAGCTGAAACTGCGGTG -BMN- Q620	300 300 50	Pan-Influenza-B	[10]

77

Table 1: Assays used for the SC2/InflA/InflB-UCT. Primers and probes were custom made and
procured from Integrated DNA Technologies (Illinois, USA), Biomers.net GmbH (Ulm, Germany) and
Ella Biotech GmbH (Martinsried, Germany). OMe, 2'O-methyl RNA; NFQ, Non-fluorescent quencher;
YakYel, Yakima Yellow

Primers and probes were diluted in MMX-R2-reagent to final concentrations as indicated above (*table 1*) to form the MMR2-Mastermix (MMRX-R2-reagent already contains the internal control assay by default). 6 ml of MMR2-Mastermix were loaded into cobas omni utility channel cassettes according to instructions by the manufacturer. The run profile for the SC2/InflA/InflB-UCT multiplex assay was configured using the cobas omni Utility Channel Software as indicated in *table 2*.

88

Software settings					
Sample type		Alcohol Based Sample (400 µL)			
Channels	1: (Not assigned)	2: <i>SC</i> 2	3: InflA	4: InflB	5: <i>IC</i>
RFI		1.25	1.25	1.25	1.15
PCR cycling conditions					
	UNG incubation	Pre-PCR step	1 st measurement	2 nd measurement	Cooling
No. of cycles		1	5	45	
No. of steps		3	2	2	
Temperature Predefined Hold time		55°C; 60°C; 65°C	95°C; 55°C	91°C; 58°C	Predefined
		120 s; 360 s; 240 s	5 s; 30 s	5 s; 25 s	
Data acquisition		None	End of each cycle	End of each cycle	

89

90 Table 2: Run-profile for the SC2/InflA/InflB, set up using the cobas omni utility channel tool.

91

92 **3.2** Limit of detection (LoD), linearity and cross-reactivity

Analytical limit of detection (LoD) was determined for all three targets simultaneously by serial dilution of reference material in Amies medium including cobas PCR Media (1:1) as matrix. For SARS-CoV-2, a stock of cell culture supernatant containing SARS-CoV-2 (11) was quantified using the SARS-CoV-2 IVD Test for the cobas6800 (12) with the Qnostics "SARS-CoV-2 Q Control 01" as reference for quantification. For Influenza-A and Influenza-B, reference material was acquired from Qnostics ("INFA Medium Q Control 01" and "INFB Medium Q Control 01") and used directly for LoD experiments. A total of 8 different

100	concentrations was tested with 8 repeats each. (SC2 [cp/ml]-InflA [cp/ml]-InflB [cp/ml],
101	1000-1000-2000, 333-333-666, 100-100-200, 50-50-100, 25-25-50, 10-10-20, 3-3-6, 1-1-2)
102	Linearity was determined for all targets simultaneously by 10-fold serial dilution, 5 repeats
103	each step, using cell culture supernatant and Vaxigrip Tetravalent Influenza vaccine (Sanofi
104	Pasteur, France) to spike Amies medium including cobas PCR Media (1:1) (<i>Figure 1</i>).
105	Inclusivity and cross-reactivity were verified using external quality control panels by
106	INSTAND e.V. (Düsseldorf, Germany) and clinical samples containing a variety of respiratory
107	pathogens, including endemic human coronaviruses (see <i>table 4</i>).

3.3 Clinical samples 108

For clinical evaluation, a total of 164 archived predetermined respiratory swab samples were 109 subjected to the SC2/InflA/InflB-UCT. Clinical samples were oropharyngeal 110 or nasopharyngeal swabs, performed using eSwab sample collection kits (Copan, Italy), 111 112 containing 1 ml Amies-Medium. 1 – 2 ml of cobas PCR Media (≤240% guanidine hydrochloride in Tris-HCL buffer) were added to samples prior to analysis in routine 113 diagnostics. Samples were stored up to three months at -20°C for SARS-CoV-2 and up to 114 115 three years for Influenza-A/B.

116 SARS-CoV-2 samples were included if positive for Target-1 and Target-2 of the SARS-CoV-2 117 IVD assay. The Cepheid Xpert Xpress Flu/RSV assay was used to resolve discrepant results for 118 Influenza-A/B virus. Samples predetermined positive (by inhouse methods) for Influenza-A 119 or Influenza-B that tested negative in the SC2/InflA/InflB-UCT were included in the study 120 only if tested positive for both Influenza-A targets or positive for Influenza-B in the Xpert 121 Xpress Flu/RSV-assay.

- 122 This work was conducted in accordance with §12 of the Hamburg hospital law (§12
- 123 HmbKHG). The use of anonymized samples was approved by the ethics committee, Freie und
- 124 Hansestadt Hamburg, PV5626.

125 4 Results

126 4.1 Analytical performance

127 Analytical LoD was determined by Probit-Analysis as 94.9 cp/ml (95% CI: 40.5 – 222.0 cp/ml)

128 for SARS-CoV-2, 14.57 cp/ml (95% CI: 6.7 – 31.6 cp/ml) for Influenza-A and 422.3 cp/ml (95%

129 CI: 213.8 – 834.4 cp/ml) for Influenza-B (*table 3*).

130

CoV-2	Influer	nza-A	Influenza-B	
Pos./Rep.*	Conc. [cp/ml]	Pos./Rep.*	Conc. [cp/ml]	Pos./Rep.*
8/8	1000	8/8	2000	8/8
8/8	333	8/8	666	8/8
8/8	100	8/8	200	7/8
8/8	50	8/8	100	8/8
8/8	25	8/8	50	6/8
6/8	10	8/8	20	5/8
0/8	3	6/8	6	2/8
3/8	1	4/8	2	0/8
0/8	0	0/8	0	0/8
	CoV-2 Pos./Rep.* 8/8 8/8 8/8 8/8 8/8 8/8 6/8 0/8 3/8 0/8	CoV-2 Influer Pos./Rep.* Conc. [cp/ml] 8/8 1000 8/8 333 8/8 100 8/8 50 8/8 50 8/8 25 6/8 10 0/8 3 3/8 1 0/8 0	CoV-2 Influenza-A Pos./Rep.* Conc. [cp/ml] Pos./Rep.* 8/8 1000 8/8 8/8 333 8/8 8/8 1000 8/8 8/8 50 8/8 8/8 50 8/8 8/8 100 8/8 8/8 100 8/8 8/8 50 8/8 6/8 10 8/8 0/8 3 6/8 3/8 1 4/8 0/8 0 0/8	CoV-2 Influenza-A Influenza-A Pos./Rep.* Conc. [cp/ml] Pos./Rep.* Conc. [cp/ml] 8/8 1000 8/8 2000 8/8 333 8/8 666 8/8 100 8/8 200 8/8 50 8/8 100 8/8 50 8/8 200 8/8 50 8/8 200 8/8 50 8/8 200 8/8 50 8/8 200 8/8 50 8/8 200 8/8 25 8/8 50 6/8 10 8/8 20 0/8 3 6/8 6 3/8 1 4/8 2 0/8 0 0/8 0

SC2/InfIA/InfIB-UCT Limit of Detection (LoD)

131

Table 3: Quantified cell culture stocks and quantified reference material (by Qnostics) was
spiked into 1:1 cobas PCR Media in eSwab medium. LOD was determined for all targets
simultaneously, meaning that every sample contained the indicated concentrations of each
pathogen for each dilution step. * Number of positives / Number of total repeats

137 The assay showed good linearity for all targets up to a CT value (cycle threshold) of 33

138 (*Figure 1*).



139

140 Figure 1: Linearity was determined for all targets simultaneously by serial dilution of SARS-

141 CoV-2 cell culture stocks and Vaxigrip Tetravalent Influenza vaccine in 1:1 cobas PCR Media

144 In cross-reactivity experiments, no false positives occurred. Avian Influenza-A strains H7N9 145 and H5N8 were correctly detected by the multiplex assay, demonstrating broad coverage 146 (*table 4*). Nonetheless, it is recommended to verify inclusivity of primer/probe sequences as 147 new Influenza-A strains continuously emerge.

¹⁴² *in eSwab medium. X-axis: dilution factor.*

External Quality Control Panel Species	Number tested	Target: SC2	Target: InflA	Target: InflB
$\ln f = 120$ A H1N1 ndm (9 (A/Michigan/45/2015)	1	Negative	Positive	Negative
Influenza A H7N9 ($A/Anhui/1/2013$)	1	Negative	Positive	Negative
Influenza A H5N8 (A/DE-	÷	Negative	1 OSICIVE	Negative
SH/Reiherente/AR8444/2016)	1	Negative	Positive	Negative
Influenza B Yamagata (B/Phuket/3073/2013)	1	Negative	Negative	Positive
Influenza B Victoria (<i>B/Colorado/06/2017</i>)	1	Negative	Negative	Positive
Human Coronavirus 229E	1	Negative	Negative	Negative
Human Coronavirus OC43	1	Negative	Negative	Negative
MERS Coronavirus	1	Negative	Negative	Negative
Parainfluenzavirus 2	1	Negative	Negative	Negative
<u>Clinical samples</u> Species	-	Target: SC2	Target: InflA	Target: InflB
Human Coronavirus HKU1	2	Negative	Negative	Negative
Human Coronavirus NL63	1	Negative	Negative	Negative
Human Coronavirus OC43	1	Negative	Negative	Negative
Boca-virus	1	Negative	Negative	Negative
Parainfluenzavirus 3	1	Negative	Negative	Negative
Human Metapneumovirus	2	Negative	Negative	Negative
Rhino-/Enterovirus	3	Negative	Negative	Negative
Respiratory Syncytial Virus	2	Negative	Negative	Negative
Mycoplasma pneumoniae	1	Negative	Negative	Negative
Chlamydia pneumoniae	1	Negative	Negative	Negative
Pneumocystis jirovecii	1	Negative	Negative	Negative

149

150 Table 4: Inclusivity and cross-reactivity. A panel of clinical samples containing respiratory

151 pathogens, as well as relevant external quality control panel samples (INSTAND e.V.) were

152 tested with the SC2/InflA/InflB-UCT. No false positives occurred.

153 **4.2 Evaluation of clinical performance**

154	Sensitivity in clinical samples containing respective targets was 98.1% for SARS-CoV-2 (52
155	samples, median CT: 31.99, IQR: 27.21 – 33.96), 97.67% for Influenza-A (43 samples of which
156	15 were subtyped as H1N1, median CT: 27.80, IQR: 24.85 – 31.1) and 100% for Influenza-B
157	(19 samples, median CT: 29, IQR: 28 - 30), see <i>table 5</i> .

		Predetermined clinical specimen			
		SARS-CoV2	Influenza-A	Influenza-B	Negative*
ЪСТ	SC2 positive	51/52	0/43	0/19	0/109
SC2/InfIA/InfIB-U	InflA positive	0/52	42/43	0/19	0/118
	InflB positive	0/52	0/43	19/19	0/142
	Negative	1/52	1/43	0/19	47/47
	Total:	52	43	19	369†

159

160

Table 5: 164 clinical samples were tested in total, predefined positive for SARS-CoV-2 via SARS-CoV-2 IVD test for the cobas6800 system; predetermined positive for Influenza-A or -B by established inhouse methods or Xpert Xpress Influenza/RSV. Invalid rate was 6.4% (invalids not included in the table). Samples were stored at -20°C between 1 and 36 months. * Total of samples negative for respective target. † Sum of all predetermined negative samples for each individual pathogen. This includes 47 samples negative for all three pathogens.

168

169 CT values showed good correlation with the SARS-CoV-2 IVD, see *figure 2*. For SARS-CoV-2 a 170 single false negative occurred for a sample containing very low amounts of viral RNA, 10

- approximately 184 cp/ml. Another false negative occurred for Influenza A in a sample with 171
- 172 low viral load (Xpert Flu/RSV, A1 CT: 33, A2 CT: 35)
- 173



175

176 Figure 2: The SC2/InflA/InflB-UCT SC2-CT was compared to the SARS-CoV-2 IVD Target-2 CT 177 (used for quantification and best in regards to linear range) to illustrate correlation with a 178 well-established assay. Red diamond indicates false negative for the multiplex assay. ND = 179 Not detected.

A total of 50 predetermined samples negative for SARS-CoV-2 (by SARS-CoV-2 IVD) and Influenza-A/B (by LDT assay) were subjected to the SC2/InflA/InflB-UCT. No false positives occurred; inhibition rate in eSwab samples was 6.4%.

As a proof of concept, a dilution series of a SARS-CoV-2 positive patient sample was prepared and subjected to testing in the presence and absence of high levels of Influenza-Aand Influenza-B-RNA (*supplement figure 1*). No relevant impact on SARS-CoV-2 detection was observed.

188

189 **5 Discussion**

190 In this study we present a functional SARS-CoV-2/Influenza-A/Influenza-B multiplex assay for 191 the cobas6800 high-throughput platform, featuring analytical and clinical performance 192 comparable to currently used methods for the detection of these pathogens in clinical 193 specimens. The ability to screen for all three viruses in a single reaction allows for 194 streamlined workflows and conservation of resources during the coming Influenza-season.

195 By this time, multiple commercial providers have announced, or are in the process of rolling 196 out multiplex-assays for detection of SARS-CoV-2, Influenza-A/B and RSV. However, these 197 are for the most part designed for a point-of-care rapid testing approach and not high-198 throughput testing. Moreover, the CDC has itself recently published primer-sets for a SARS-199 CoV-2/Influenza-A/Influenza-B multiplex assay, which relies on manual PCR workflows (10). 200 However, the ability to employ inhouse assays on fully automated PCR platforms provides 201 vastly improved scalability of testing capacity and less limitations due to availability of 202 trained personnel.

203 Most currently available commercial SARS-CoV-2 tests with FDA emergency authorization 204 are designed as multi-target assays to account for emerging mutations. While the original 205 Sarbeco-E primerset by Corman et al. (6) resides in a particularly stable region of the SARS-206 CoV-2 genome, single mutations have been reported within the ever-growing catalogue of 207 available whole genome sequences (13). The RdRp/Hel assay by Chan et al. (7) was modified and adapted as a second target to provide additional security for inclusivity in SARS-CoV-2 208 209 detection. Both assays were allocated to the same channel as positivity of any single one 210 would constitute a positive result. There was no indication that presence of Influenza-A 211 and/or Influenza-B RNA within the reaction substantially impairs sensitivity for SARS-CoV-2. 212 If necessary, each SARS-CoV-2 assay can be analysed separately by moving RdRp/Hel 213 detection to channel 1, using the following probe (or comparable): 5' Atto425-214 TTAAGATGT(BMN-Q535)GGTGCTTGCATACGTAGAC -BMN-Q535 3' (see supplement figure 2). 215 It has to be acknowledged that the SARS-CoV-2 assays used for this multiplex-setup are technically not specific for SARS-CoV-2 but for the Sarbeco-subgenus of betacoronaviruses, 216 217 including SARS-CoV (from 2003) and SARS-like bat viruses.

In conclusion, we provide analytical and clinical evaluation of a SARS-CoV-2/Influenza-A/Influenza-B multiplex assay for the cobas6800 high-throughput platform. Performance for each target was comparable to existing solutions currently in use in diagnostic practice. Our novel assay may prove useful for streamlining diagnostics during the upcoming Influenzaseason.

223

6 Author contribution

- 225 Conceptualization: DN, MA, SP, and ML. Methodology and Investigation: DN. Original draft
- 226 preparation: DN and SP. Review and editing: DN, AH, MA, SP and ML Supervision: SP and ML.
- 227 All authors agreed to the publication of the final manuscript.

228

7 Competing interest

- 230 ML received speaker honoraria and related travel expenses from Roche Diagnostics.
- 231 All other authors declare no conflict of interest.

232

233 References:

234	1.	Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons From the Coronavirus
235		Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the
236		Chinese Center for Disease Control and Prevention, JAMA doi:10.1001/iama.2020.2648.

- Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton
 KE. 2020. Coronavirus Disease 2019 Case Surveillance United States, January 22-May 30,
 2020. MMWR Morbidity and mortality weekly report 69:759-765.
- 2403.Eigner U, Reucher S, Hefner N, Staffa-Peichl S, Kolb M, Betz U, Holfelder M, Spier G, Pfefferle241S, Lutgehetmann M. 2019. Clinical evaluation of multiplex RT-PCR assays for the detection of242influenza A/B and respiratory syncytial virus using a high throughput system. J Virol Methods243269:49-54.
- Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. 2020. Evaluation of a quantitative RT-PCR
 assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput
 system. Eurosurveillance 25:2000152.
- Poljak M, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, Avšič Županc T,
 Petrovec M. 2020. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform
 switch during 48 hours in the midst of the COVID-19 pandemic. Journal of Clinical
 Microbiology doi:10.1128/jcm.00599-20.JCM.00599-20.
- Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S,
 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,

254Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-255time RT-PCR. Euro Surveill 25.

- Chan JF-W, Yip CC-Y, To KK-W, Tang TH-C, Wong SC-Y, Leung K-H, Fung AY-F, Ng AC-K, Zou Z, Tsoi H-W, Choi GK-Y, Tam AR, Cheng VC-C, Chan K-H, Tsang OT-Y, Yuen K-Y. 2020. Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens. Journal of Clinical Microbiology 58:e00310-20.
- 2618.WHO. 2017. WHO information for the molecular detection of influenza viruses. WHO262Website.
- 2639.Terrier O, Josset L, Textoris J, Marcel V, Cartet G, Ferraris O, N'Guyen C, Lina B, Diaz J-J,264Bourdon J-C, Rosa-Calatrava M. 2011. Cellular transcriptional profiling in human lung265epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-266regulation of the host p53 pathway. Virology journal 8:285-285.
- 26710.CDC. 2020. Research Use Only CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay Real-Time268RT-PCR Primers and Probes. CDC Website.
- Pfefferle S, Huang J, Nörz D, Indenbirken D, Lütgehetmann M, Oestereich L, Günther T,
 Grundhoff A, Aepfelbacher M, Fischer N. 2020. Complete Genome Sequence of a SARS-CoV-2
 Strain Isolated in Northern Germany. Microbiology Resource Announcements 9:e00520-20.
- 272 12. Nörz D, Frontzek A, Eigner U, Oestereich L, Fischer N, Aepfelbacher M, Pfefferle S, 273 Lütgehetmann M. 2020. Pushing beyond specifications: Evaluation of linearity and clinical 274 performance of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in 275 other materials outside recommendations. blood and medRxiv 276 doi:10.1101/2020.05.28.20115469:2020.05.28.20115469.
- 277 13. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, Petrone ME, Casanovas-278 Massana A, Catherine Muenker M, Moore AJ, Klein J, Lu P, Lu-Culligan A, Jiang X, Kim DJ, 279 Kudo E, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Tokuyama 280 M, Venkataraman A, Weizman O-E, Wong P, Yang Y, Cheemarla NR, White EB, Lapidus S, Earnest R, Geng B, Vijayakumar P, Odio C, Fournier J, Bermejo S, Farhadian S, Dela Cruz CS, 281 282 Iwasaki A, Ko AI, Landry ML, Foxman EF, Grubaugh ND. 2020. Analytical sensitivity and 283 efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nature Microbiology 284 doi:10.1038/s41564-020-0761-6.

286

285

288 8 Figure legend

289 **8.1 Figure 1**

- 290 Figure 1: Linearity was determined for all targets simultaneously by serial dilution of SARS-
- 291 CoV-2 cell culture stocks and Vaxigrip Tetravalent Influenza vaccine in 1:1 cobas PCR Media
- 292 in eSwab medium. X-axis: dilution factor.

293

294 8.2 Figure 2

295 Figure 2: The SC2/InflA/InflB-UCT SC2-CT was compared to the SARS-CoV-2 IVD Target-2 CT

296 (used for quantification and best in regards to linear range) to illustrate correlation with a

297 well-established assay. Red diamond indicates false negative for the multiplex assay. ND =

298 Not detected.

299 8.3 Supplement Figure 1

Supplement Figure 1: A patient sample was used for two 10-fold dilution series in 1:1 cobas PCR
 Media and eSwab medium, one containing Vaxigrip tetravalent Influenza vaccine in order to rule out
 relevant interference of high levels of Influenza-RNA for SARS-CoV-2 detection.

303 8.4 Supplement Figure 2

304 Supplement Figure 2: Amplification curves of the SC2/InflA/InflB-UCT using a Atto425 probe for 305 detection of RdRp/Hel on channel one. In this fashion, both SARS-CoV-2 targets can be analyzed

- 306 separately. This leads to increased cross-talk of the Yakima-Yellow probe into Channel 2 due to lower
- 307 background fluourescence.